Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:35:34 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:ABEO - ABEONA THERAPEUTICS INC - https://abeonatherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ABEO - Q0.14.90·5.600.25.13+0.234.7878.74,2614,3154.99  5.16  4.93017.5401  3.932819:42:50Dec 3115 min RT 2¢

Recent Trades - Last 10 of 4315
Time ETExPriceChangeVolume
19:42:50Q5.09970.199715
19:28:41Q5.100.201,000
18:59:05Q5.1150.21520
18:47:38Q5.160.26100
17:35:29Q5.180.281
17:29:43Q5.03250.1325100
17:10:02Q5.210.3118
16:36:02Q5.03250.132540
16:10:04Q5.130.231
16:10:04Q5.130.231

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-12-31 07:30U:ABEONews ReleaseAbeona Therapeutics(TM) Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-12-15 07:30U:ABEONews ReleaseAbeona Therapeutics(TM) Announces Appointment of Mohamad Tabrizi as Chief Business Officer
2025-12-11 07:30U:ABEONews ReleaseAbeona Therapeutics(TM) Announces New Qualified Treatment Center for ZEVASKYN(TM) in Texas
2025-12-08 07:30U:ABEONews ReleaseAbeona Therapeutics(TM) Announces First Patient Treatment with ZEVASKYN(TM) Gene Therapy
2025-12-01 07:30U:ABEONews ReleaseAbeona Therapeutics(TM) Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-12 07:30U:ABEONews ReleaseAbeona Therapeutics(TM) Reports Third Quarter 2025 Financial Results and Corporate Updates
2025-11-07 07:30U:ABEONews ReleaseAbeona Therapeutics(TM) Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation
2025-11-03 07:30U:ABEONews ReleaseAbeona Therapeutics(TM) Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-10-30 10:45U:ABEONews ReleaseAbeona Therapeutics(TM) Announces Permanent J-Code for ZEVASKYN(TM) (prademagene zamikeracel)
2025-10-20 08:30U:ABEONews ReleaseAbeona Therapeutics(TM) Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs
2025-10-13 07:30U:ABEONews ReleaseAbeona Therapeutics(TM) Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program
2025-10-08 07:30U:ABEONews ReleaseAbeona Therapeutics(TM) and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN(TM) Gene Therapy
2025-10-01 07:30U:ABEONews ReleaseAbeona Therapeutics(TM) Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-09-02 07:30U:ABEONews ReleaseAbeona Therapeutics(TM) Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-08-29 07:30U:ABEONews ReleaseAbeona Therapeutics(TM) Announces Participation in Upcoming Investor Conferences
2025-08-14 07:30U:ABEONews ReleaseAbeona Therapeutics(TM) Reports Second Quarter 2025 Financial Results and Corporate Updates
2025-08-01 07:30U:ABEONews ReleaseAbeona Therapeutics(TM) Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-07-29 10:00U:ABEONews ReleaseAscellaHealth HUB Partnership with Abeona Therapeutics(TM) Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients
2025-07-15 07:30U:ABEONews ReleaseZEVASKYN(TM) Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area
2025-07-14 07:00U:ABEONews ReleaseBio-Techne's Simple Western(TM) Technology Utilized in Recent FDA Approval of ZEVASKYN(TM) Cell-Based Gene Therapy